Cancers (Jan 2021)

Enhanced Expression of <i>miR-181b</i> in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response

  • Mirco Di Marco,
  • Serena Veschi,
  • Paola Lanuti,
  • Alice Ramassone,
  • Stefania Pacillo,
  • Sara Pagotto,
  • Felice Pepe,
  • Jonahunnatha Nesson George-William,
  • Claudia Curcio,
  • Marco Marchisio,
  • Sebastiano Miscia,
  • Idanna Innocenti,
  • Francesco Autore,
  • Barbara Vannata,
  • Patrizia Di Gregorio,
  • Mario Di Gioacchino,
  • Silvia Valentinuzzi,
  • Manuela Iezzi,
  • Renato Mariani-Costantini,
  • Luigi Maria Larocca,
  • Luca Laurenti,
  • Angelo Veronese,
  • Rosa Visone

DOI
https://doi.org/10.3390/cancers13020257
Journal volume & issue
Vol. 13, no. 2
p. 257

Abstract

Read online

The clinical progression of B cell chronic lymphocytic leukemia (CLL) is associated with immune cell dysfunction and a strong decrease of miR-181b-5p (miR-181b), promoting the death of CLL cells. Here we investigated whether the reduction of miR-181b impairs the immune response in CLL. We demonstrate that activated CD4+ T cells increase miR-181b expression in CLL through CD40–CD40L signaling, which enhances the maturation and activity of cytotoxic T cells and, consequently, the apoptotic response of CLL cells. The cytotoxic response is facilitated by a depletion of the anti-inflammatory cytokine interleukin 10, targeted by miR-181b. In vivo experiments in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice confirmed that miR-181b promotes the apoptotic death of CLL cells only when functional T cells are restored. Overall, our findings suggest that the reinstatement of miR-181b in CLL cells could be an exploitable adjuvant therapeutic option for the treatment of CLL.

Keywords